Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children

NCT ID: NCT01044030

Last Updated: 2018-06-20

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

326 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the proposed study is to determine the effectiveness and safety of orally administered viscous-adherent xylitol syrup given in a dose of five grams three times daily for 12 weeks in reducing the incidence of clinically-diagnosed acute otitis media (ear infection) in children with a history of recurrent acute otitis media.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Otitis Media

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xylitol syrup

Group Type EXPERIMENTAL

Xylitol syrup

Intervention Type DRUG

7.5 mL (5 grams) by mouth three times daily

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

7.5 mL by mouth three times daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xylitol syrup

7.5 mL (5 grams) by mouth three times daily

Intervention Type DRUG

Placebo

7.5 mL by mouth three times daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Six months to five years of age
* General good health
* History of at least three episodes of AOM in previous 12 months, at least one of which occurred within the previous six months
* English or Spanish speaking

Exclusion Criteria

* History of tympanostomy tubes
* Intestinal malabsorption or chronic diarrhea
* Diabetes mellitus
* Any inborn error of metabolism
* Parent/guardian unreachable by telephone
* Known allergy to any of the study solution components (xylitol, sorbitol, sodium carboxymethylcellulose, potato starch, glycerin, potassium sorbate, natural berry flavoring).
Minimum Eligible Age

6 Months

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIH

Sponsor Role collaborator

Boston Children's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Louis Vernacchio

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Louis Vernacchio, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

Boston Children's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital Boston

Boston, Massachusetts, United States

Site Status

Slone Epidemiology Center at Boston University

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Vernacchio L, Vezina RM, Mitchell AA. Tolerability of oral xylitol solution in young children: implications for otitis media prophylaxis. Int J Pediatr Otorhinolaryngol. 2007 Jan;71(1):89-94. doi: 10.1016/j.ijporl.2006.09.008. Epub 2006 Nov 9.

Reference Type BACKGROUND
PMID: 17097152 (View on PubMed)

Vernacchio L, Corwin MJ, Vezina RM, Pelton SI, Feldman HA, Coyne-Beasley T, Mitchell AA. Xylitol syrup for the prevention of acute otitis media. Pediatrics. 2014 Feb;133(2):289-95. doi: 10.1542/peds.2013-2373. Epub 2014 Jan 6.

Reference Type RESULT
PMID: 24394686 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC1DC010668-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

09-09-0455

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Study New Gel for Xerostomia
NCT04184908 UNKNOWN PHASE1
Burning Mouth Syndrome: Symptoms and Management
NCT07016555 RECRUITING EARLY_PHASE1
Green Tea Lozenges for the Management of Dry Mouth
NCT01647737 COMPLETED PHASE1/PHASE2
Local Pilocarpine for Relieving Dry Mouth
NCT04195100 COMPLETED EARLY_PHASE1